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Abstract
Background: Previous evidence has demonstrated that serum leptin is correlated with appetite in combination with, but
not without, modest exercise. Aim: The present experiments investigated the effects of exogenous adrenaline and a/b
adrenoceptor blockade in combination with moderate exercise on serum leptin concentrations, appetite/satiety sensa-
tions and subsequent food intake in obese women. Methods: A total of 10 obese women ((mean+ SEM), age: 50 (1.9)
years, body mass index 36 (4.1) kg/m2, waist 104.8 (4.1) cm) participated in two separate, double-blind randomised
experimental trials. Experiment 1: moderate exercise after a/b adrenergic blocker (labetalol, 100 mg orally) versus
moderate exercise plus placebo; experiment 2: adrenaline infusion for 20 minutes versus saline infusion. Appetite/satiety
and biochemistry were measured at baseline, pre- and immediately post-intervention, then 1 hour post-intervention (i.e.,
before dinner). Food intake was assessed via ad libitum buffet-style dinner. Results: No differences were found in
appetite/satiety, subsequent food intake or serum leptin in any of the studies (experiment 1 or experiment 2). In
experiment 1, blood glucose was higher (p < 0.01) and plasma free fatty acids lower (p ¼ 0.04) versus placebo.
In experiment 2, plasma free fatty acids (p < 0.05) increased after adrenaline versus saline infusion.Conclusions:Neither
inhibition of exercise-induced adrenergic activity by combined a/b adrenergic blockade nor moderate increases in
adrenergic activity induced by intravenous adrenaline infusion affected acute appetite regulation.
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Introduction
Obesity is the most prevalent single disease in the world
(International Classification of Diseases 10 code E.66), with
more than 2.1 billion overweight adults (Ng et al., 2013).
Better understanding of the mechanisms that regulate food
intake, energy expenditure (EE) and energy balance is crit-
ical for the prevention and management of obesity. Physical
activity has been implicated in appetite and body mass
regulation; appetite also seems to be ‘coupled’ with body
weight control in individuals undertaking moderate physical
activity (Shook et al., 2015). Although physical activity
tends to increase food intake (Westerterp et al. 2015),
habitual exercisers are able to closely match food intake to
EE (Martins et al., 2008); however, the mechanism under-
pinning the coupling between physical exercise and food
intake regulation has yet to be explained.
In experimental rodent models and in cases of con-
genital obesity, leptin is a key regulator promoting satiety
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(Farooqi et al., 2009). In humans, leptin concentration is
closely correlated to total fat mass (FM; Considine et al.,
1996) and physical activity strongly predicts circulating
leptin concentrations independently of body FM, suggest-
ing a plausible role of physical activity in leptin sensitivity
(Chu et al., 2001). Raised circulating leptin concentrations
do not appear to prevent overeating in obese humans, who
are considered ‘leptin resistant’ (Lean and Malkova, 2016).
Indeed, most models of diet-induced obesity in rodents
have presented evidence that obesity causes central and
peripheral leptin resistance whereby anorexigenic/orexi-
genic neurons fail to signal satiety in response to high
circulating leptin (Morris and Rui, 2009). Leptin’s trans-
port across the blood-brain barrier is also reduced con-
currently with increasing adiposity (Banks and Farrell,
2003). As human obesity is associated with impaired
appetite control, this implies that other factors may influ-
ence the anorexic effects of leptin.
Several studies have demonstrated the acute regulation
of circulating leptin turnover by adrenergic agents and
catecholamine (Keller et al., 2005; Scriba et al., 2000) and
the role of endogenous catecholamine in the hypothalamic
paraventricular nucleus (PVN) has been related to eating
or satiety (Wellman, 2000). For example, activation of
a2-adrenoceptors in the PVN enhances eating, whereas
activation of a1-adrenoceptors inhibits eating (Wellman
et al., 1993). Moreover, an acute effect of elevated adre-
naline levels on enhanced leptin transport into the brain
through activation of predominantly a1-adrenoceptors was
found in rats (Banks, 2001). A link between obesity, inac-
tivity and raised circulating leptin concentrations has been
clearly demonstrated (Chu et al., 2001), which suggests that
high circulating leptin concentrations are ineffective in
regulating appetite and body mass when physically inactive.
Studies in lean and obese rats suggested that acute and
chronic exercise improved the antiorexigenic action of lep-
tin, as well as hypothalamic leptin signalling (Krawczewski
et al., 2011; Ropelle et al., 2010).
We also reported an association between circulating
leptin and appetite suppression in obese individuals, but only
following an acute bout of moderate-intensity exercise
(Tsofliou et al., 2003). These studies support a role of
exercise in mediating the action of leptin on appetite regu-
lation in the short term. As even light exercise is known to
produce a marked stress response in sedentary individuals
(Salvadori et al., 2003), the increase in catecholamines that
normally accompanies such a response might be responsible
for the coupling of leptin and appetite. Adrenaline may
facilitate leptin transport into the brain through stimulation
of a-adrenoceptors located at the blood side of the blood-
brain barrier (Banks, 2001). The purpose of the current study
was to investigate the effects of increased circulating adre-
naline concentrations by exogenous intravenous adminis-
tration and the effects of moderate exercise performed
during a/b-adrenoceptor blockade on our primary outcomes,
appetite-satiety measures and on subsequent food intake in
obese women. We also investigated the impact of these
interventions on biological markers such as circulating lep-
tin, glucose and free fatty acid (FFA) concentrations, using
the association between serum leptin and appetite/satiety
sensations as an indirect index of leptin sensitivity.
Material and methods
This study is reported according to the CONSORT guide-
lines (Schulz et al., 2010) (Figure S1 and Table S1 in
Supplementary Files).
Participants
A total of 10 (n ¼ 10) obese but otherwise healthy, pre-
menopausal women (Table 1) gave written informed con-
sent to participate in the study, which was conducted in
accordance with the Declaration of Helsinki. The sample
size used in this study was based on the primary outcomes
of interest such as appetite ratings and ad libitum intake.
Using a paired design and a power of 0.8, a minimum of
nine participants would be needed to detect a 10mm dif-
ference in postprandial ratings and to detect a 100 kcal
difference in ad libitum energy intake (EI) (Lara et al.,
2010; Horner et al., 2014). The protocol was approved by
the Glasgow Royal Infirmary Research Ethics Committee
(01HU009, 02HU002). All participants were in good
physical and mental health with normal blood pressure
( 140 /  90 mmHg), non-smokers, on no medication
known to affect appetite, not known to be anaemic or
hyperlipidemic and not on a special diet. Following elig-
ibility screening and familiarisation with methodological
procedures, using a double-blind, crossover design, partici-
pants were randomised to the intervention for each experi-
ment (EXP-1 and EXP-2) using an online random number
generator (http://www.randomization.com). The order of the
trials for each experiment was randomised separately. There
was an interval of at least 7 days between trials. In EXP-1
(exercise with either a/b-adrenoceptor blocker or placebo)
all 10 eligible participants took part in the study procedures
and data analysis whereas in EXP-2 (adrenaline vs saline
infusion) results are presented from nine participants; one
participant did not continue after EXP-1.
Table 1. Subject characteristics, n ¼ 10.
Age (years) 50.3 + 1.9
Weight (kg) 90.2 + 5.2
Height (cm) 158.0 + 0.02
BMI (kg.m2) 36.0 + 4.1
Waist circumference (cm) 104.8 + 4.1
Hip circumference (cm) 115.2 + 3.1
Fat mass (%) predicted by waist measurement 47.7 + 1.7
Systolic blood pressure (mmHg) 129.6 + 2.4
Diastolic blood pressure (mmHg) 89.2 + 1.4
Values are mean+ SEM.
BMI: body mass index.
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Concealed treatment allocation was implemented; a
person, unrelated to the trial, prepared the treatment allo-
cation using sealed opaque envelopes. Both participants
and researchers evaluating the impact of the experiments
were blinded to treatment. Intervention agents were dis-
pensed at each visit by two members of the staff not
involved in the study.
Experimental design and procedures
Adrenaline was infused (MacCarthy and Bloomfield,
1983; Centers for Disease Control, 2014), raising circu-
lating adrenaline levels to those typically seen during
moderate exercise (Lean et al., 1996). On a separate
occasion, labetalol, which blocks a1-, b1- and b2-adreno-
ceptors (MacCarthy and Bloomfield, 1983; McLoughlin
et al., 1992) was administered prior to moderate exercise.
Participants visited the laboratory on four occasions to
participate in four acute interventions with an interval of
at least 7 days between trials (Figure 1); EXP-1 involved
moderate-intensity exercise with either a/b-adrenoceptor
blocker or placebo and EXP-2 adrenaline infusion versus
saline infusion. Participants kept diet and physical activity
records for 2 days preceding the first experimental trial.
These food and activity patterns were replicated before all
subsequent trials. Household measures (e.g., glasses,
cupfuls, tablespoons, slices, etc.) were used to quantify
food and fluid consumption. For each experiment, parti-
cipants visited the laboratory approximately 5 hours after
a standard lunch and the time duration was standardised
within subject. On arrival at the laboratory, weight, waist
and hip circumference were measured using calibrated
scales and inextensible tapes with bone landmarks for
anthropometry (Centers for Disease Control, 2014). The
body fat percentage was predicted from waist (Lean et al.,
1996). Arterialised-venous blood samples (McLoughlin
et al., 1992) were collected from an 18G indwelling
catheter placed by percutaneous puncture into a vein on
the dorsum of a heated hand and a baseline sample (-60
minutes) was taken. Serial blood samples (10 ml) were
then drawn at 0, 20 and 80 minutes. Following each
blood sample, participants completed a set of self-rating
100 mm visual analogue scales for hunger, desire to eat,
prospective food consumption (PFC), satiety and fullness
(Stubbs et al., 2000). Throughout each trial, participants
were seated in a comfortable environment watching food-
related digital versatile DVDs for 60 minutes. Food-
related DVDs were intended to direct participants’
attention towards food and eating, to stimulate a familiar
form of home entertainment that might reduce anxiety and
eating restraint (Bellisle and Dalix, 2001).
After watching the food-related DVDs, participants took
part in one of the following interventions on each of the
4 study days. In EXP-1, 60 minutes prior to each of the
two exercise trials, participants were given either 100 mg
labetalol (Generics UK) or placebo (calcium carbonate).
Then the participants were required to walk at a moderate
pace (5 km/h) on a motorised treadmill for 20 minutes. This
is in line with a previous study of our group that found
acute leptin coupling with appetite/satiety measures after
a bout of moderate intensity exercise in obese women
(Tsofliou et al., 2003).
In EXP-2, a single dose of either adrenaline hydro-
chloride (i.e., 1:10,000) diluted in normal saline, or normal
saline alone was infused intravenously at a rate of 12.5 ng
min/kg ideal body mass, via a pump for 20 minutes
(Webber et al., 1994) to yield a plasma level not exceeding
1 nmol/L. This dosage ensures the plasma catecholamine
concentration will not exceed the level typically measured
following moderate-intensity exercise (Gustafson et al.,
1990). This dosage aimed to maintain catecholamine con-
centrations similar to the levels attained by the 20 minutes
of moderate exercise (McLoughlin et al., 1992). The DVD
was switched off for 20 minutes during each infusion.
Following each intervention, participants continued
watching food-related DVDs for another hour. They were
then offered a buffet-type dinner comprising 11 food items:
roasted chicken breast (200 g), roasted baby potatoes
(160 g), onion stuffing (60 g), boiled peas (126 g), boiled
carrots (116 g), boiled corn (118 g), tuna cucumber sand-
wich (176 g), chicken and salad sandwich (178 g), banana
(100 g), two apple pies (120 g), potato crisps (26 g) and
orange juice (500 ml) and were told to eat as much as they
wanted within 1 hour. Each person’s selection from the
buffet dinner was analysed for EI and macronutrient
Figure 1. Schematic representation of the study design, EXP 1: Moderate exercise plus adrenergic blocker vs. placebo for 20 min; EXP
2: Adrenaline vs. Saline infusion for 20 min.
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content using a computerised version of McCance and
Widdowson’s (revised by Holland et al., 1993) food com-
position tables and relative EI (REI) was calculated for both
exercise trials in EXP-1 as EI minus the energy cost of the
exercise (Douglas et al., 2015).
Rating of perceived exertion (breathlessness and leg
exertion) (Borg, 1982) and heart rate (HR) (Polar Sport
Tester, Polar Electro Oy, Finland) were recorded every 10
minutes during the moderate exercise and the infusion
interventions. For EXP-1, expired gas was collected in
Douglas bags for 5 minutes at rest, and thereafter 1 minute
collections were obtained every 10 minutes during the
moderate exercise interventions. Expired gases were ana-
lysed within 5 minutes of collection for O2 (Servomex
570A, East Sussex, UK) and CO2 (Servomex 1400 B4, East
Sussex, UK), volume (dry gas meter, Harvard Apparatus
Ltd., Hertfordshire, UK) and temperature (C6600 10-
Channel Microprocessor, Comark, Hertfordshire, UK).
Barometric pressure was measured using a standard mer-
cury barometer. Oxygen uptake (VO2), carbon dioxide
production (VCO2) and respiratory exchange ratio (RER,
i.e., VO2/VCO2) were subsequently evaluated and the
percentages of fuel oxidation were determined. EE
(kcalmin1) (Ravussin et al., 1985) and the rates of fat and
carbohydrate oxidation (gmin1) (Alkahtani, 2014) were
calculated by standard equations: EE ¼ {4.686 þ [(RER 
0.707) / 0.293] x 0.361} x VO2; fat oxidation ¼ (1.67 x
VO2)  (1.67 x VCO2); carbohydrate oxidation ¼ (4.55 x
VCO2)  (3.21 x VO2).
Blood treatment and analyses
Venous blood was collected in K3EDTA vacutainers for
the measurement of blood glucose, plasma free fatty acids
(FFA) (colorimetric method, Boehringer Mannheim Bio-
chemica, London, UK) and into clot activator vacutainers
for serum leptin measurement. Duplicate aliquots (400 ml)
of whole blood from the K3EDTA tube were rapidly
deproteinised in 800 ml of 0.3 mol.l1 perchloric acid;
following centrifugation the supernatant was used for the
measurement of glucose (Maughan, 1982). Plasma super-
natant was separated and plasma (500 l) was mixed with
50 ml EGTA-glutathione and stored at -70C for subsequent
determination of adrenaline and noradrenaline (NA) (For-
ster and Macdonald, 1999). The remaining plasma was
stored at20C and later used for the measurement of FFA
(colorimetric method, Boehringer Mannheim Biochemica,
London, UK). Blood collected in the clot activator vacu-
tainer was allowed to clot for 10 minutes. Following cen-
trifugation, the serum was stored at -70C and subsequently
analysed for leptin by radioimmunoassay.
Statistical analysis
Statistical analyses were carried out with IBM SPSS v22
for Windows. To assess the impact of interventions, sta-
tistical analysis of the data was carried out using General
Linear Model with repeated measures followed by pairwise
analysis with Bonferroni adjustment. Results are presented
as estimated marginal means+ SEM. Correlation analysis
was also carried out between the serum leptin concentra-
tions and appetite measures (for each time point separately)
and adiposity indices. Statistical significance was taken as
p < 0.05.
Results
Effects on self-reported appetite-satiety ratings and
subsequent dietary intake
Profiles of hunger, desire to eat, PFC, fullness and satiety
throughout each intervention in both experiments are
shown in Figures 2(a) and 2(b). In both EXP-1 and EXP-2,
a main time effect was observed in all appetite-satiety
measures and there were no significant differences on
appetite/satiety measures between interventions.
In EXP-1, the general linear model showed a signif-
icant time effect for hunger ratings (p ¼ 0.003), satiety,
desire to eat and for PFC ratings (p ¼ 0.002). No dif-
ferences were found over time in PFC or fullness ratings
(Figure 2(a), left side). In EXP-2 there was a significant
time effect for hunger, satiety, fullness, PFC and for the
desire to eat (p < 0.001) (Figure 2(b), right side).
Self-selected food intake at dinner did not differ
significantly between trials in either EXP-1 or EXP-2
(Table 2).
Effects on biochemical measures in both experiments
In EXP-1 there was no effect of intervention (p ¼ 0.6) and
time by intervention interaction (p ¼ 0.4) for serum leptin.
Significant differences were found in blood glucose and
plasma FFA between the two moderate exercise interven-
tions. Blood glucose concentrations were significantly
higher and plasma FFA was significantly lower for 1 hour
after the moderate exercise plus a/b blocker intervention
compared to exercise plus placebo (Table 3).
In EXP-2 there was no significant difference on serum
leptin concentrations and blood glucose concentrations
between the adrenaline and the saline infusions or over
time, throughout the trials (p > 0.05). Plasma concentra-
tions of FFA were significantly higher immediately after
the adrenaline infusion compared to saline infusion (FFA,
p¼ 0.032). In addition, plasma NA concentrations showed
a borderline significant difference between treatments
(Table 4).
Baseline serum leptin concentrations correlated signif-
icantly with body mass index (BMI, kg.m2), FM (%) and
waist circumference (BMI r¼ 0.78, p¼ 0.01, FM r¼ 0.63,
p ¼ 0.04, waist r ¼ 0.71, p ¼ 0.02). No significant asso-
ciations were found between serum leptin concentrations
and appetite-satiety measures at any time point in the two
experiments (p > 0.05).
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Physiological responses to treadmill walking and
adrenaline infusion
HR, perceived breathlessness and leg tiredness during
the moderate exercise and the infusion interventions
are show in Table 5; there was no significant difference
in HR between trials in either EXP-1 or EXP-2 (Table
5). The average EE of participants was 136 kcal (+ 30)
and 128 (+ 40) in exercise plus placebo and exercise
plus a/b blocker respectively; the EE was not signifi-
cantly different between exercise trials. In both EXP-1
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Figure 2. Mean+ SEM profiles of self-reported appetite-satiety ratings in the Moderate exercise plus a/b blocker () and Moderate
exercise plus placebo () trials (2a, left side), and in the Adrenaline infusion (&) and Saline infusion (c) trials (2b, right side); §||: are
significantly different from baseline within the Moderate exercise plus a/b blocker (§) or the Moderate exercise plus placebo (||) trial
and within the Adrenaline infusion (&§) or the Saline infusion trials (c||), p < 0.001.
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and EXP-2, oxygen uptake (VO2), carbon dioxide
production (VCO2), RER and fuel Fat, Carbohydrate
(CHO) oxidation rates were not significantly different
between trials (Table 6).
Discussion
In the current study, we examined the effects of exogenous
adrenaline and a-/b-adrenoceptor blockade in combination
with moderate exercise on serum leptin concentration,
appetite/satiety sensations and food intake in obese women.
It was envisaged that this approach would allow us to
identify whether adrenergic stimulation mediates the cen-
tral effect of leptin on appetite regulation. The novel result
of the current study is that moderate manipulation of adre-
nergic activity via adrenaline infusion or a/b-adrenoceptor
blockade using 100 mg labetalol during moderate-
intensity exercise was not found to affect post-exercise
appetite/satiety sensations and subsequent EI in obese
women.
Previous studies have shown impaired catecholamine
responses to physical exercise in obese individuals
(Salvadori et al., 2003). In the current study, plasma NA
concentration increased to 2.3 nmoll1 at the end of the
adrenaline infusion (only borderline significance was
found), typical of the suppressed levels found during
exercise in obesity; substantial variation was reported in
NA concentration during intense or exhaustive exercise in
obese, young individuals (from 4.28 to 5.9 nmoll1)
(Zouhal et al., 2013). HR tended to increase towards the
end of the adrenaline infusion (82 b.min1) at similar levels
with previous adrenaline infusion studies in obese women
(Walsh et al., 1998) but we did not observe significant
differences; plasma FFA reached concentrations of 1.09
mmoll1, which is indicative of adrenaline-stimulated
lipolysis (Webber et al., 1994). We were not able to
determine post-adrenaline infusion values of circulating
Table 2. Buffet-style dinner intake subsequent to all interventions.
Dietary intake
Exercise
plus placebo, n ¼ 10
Exercise
plus a/b blocker, n ¼ 10 p value
Adrenaline
infusion, n ¼ 9
Saline
infusion, n ¼ 9 p value
Energy intake (kcal) 812.7 + 75.9 899.9+ 64.7 0.23 1023.3+ 81.2 1013.2 + 79.7 0.85
Protein (g) 57.1 + 6.6 59.2+ 5.5 0.48 67.8+ 7.6 65.2 + 6.1 0.43
Protein (%) 28 + 1.6 27+ 2.3 0.67 26.5+ 2.2 27 + 2.1 0.92
Carbohydrate (g) 103.4 + 8.2 112.8+ 7.9 0.41 124.9+ 9.6 120.2 + 11.5 0.43
Carbohydrate (%) 50 + 2.7 48+ 3.1 0.62 47+ 2.8 45 + 1.7 0.10
Fat (g) 21.5 + 2.7 26.1+ 3.6 0.17 31.3+ 3.4 33.1 + 3.4 0.48
Fat (%) 22 + 1.5 25+ 6.8 0.30 26+ 1.3 28 + 4.2 0.06
Data are shown as mean+ SEM; no significant differences between interventions in both EXP-1 and EXP-2 (paired t-test).
EXP: experiment.
Table 3. Serum leptin, blood glucose, plasma FFA during EXP-1, n ¼ 10.
Interventions (-60 min) (0 min) (20 min) (80 min) Time Intervention
Intervention
x time
Serum leptin
(ng.ml1)
Exercise plus
placebo
62.28+ 6.99 65.71 + 8.39 73.01 + 8.45 65.65 + 7.41 p ¼ 0.0004 p ¼ 0.694 p ¼ 0.406
Exercise plus
a/b blocker
62.75+ 7.27 63.37 + 7.33 68.90 + 7.5 65.24 + 7.84
Blood
glucose
(mmol.l1)
Exercise plus
placebo
4.63 + 0.16 4.53 + 0.08 4.55 + 0.09 4.52 + 0.06 p ¼ 0.659 p ¼ 0.0004 p ¼ 0.028
Exercise plus
a/b blocker
4.59 + 0.16 4.83 + 0.11 4.91 + 0.07a 4.89 + 0.06a
Plasma FFA
(mmol.l1)
Exercise plus
placebo
0.61 + 0.13 0.65 + 0.08 0.74 + 0.09 0.73 + 0.07 p ¼ 0.866 p ¼ 0.101 p < 0.001
Exercise plus
a/b blocker
0.67 + 0.11 0.59 + 0.07 0.49 + 0.06a 0.59 + 0.06a
Values are estimated marginal means+ SEM. Analysis was conducted by GLM with repeated measures adjusted for multiple comparisons using
Bonferroni corrections.
aSignificant differences between exercise interventions (exercise plus a/b blocker vs exercise plus placebo: glucose 20 minutes, p ¼ 0.001, 80 minutes
(after dinner) p < 0.001; FFA 20 minutes, p ¼ 0.02, 80 minutes (after dinner) p ¼ 0.005).
EXP: experiment; FFA: free fatty acids; GLM: General Linear Model.
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adrenaline concentrations due to unresolved peaks
co-eluting with adrenaline. However, the plasma FFA
profiles would be consistent with responses to plasma
adrenaline concentrations above 0.6 nmoll1 (*0.8
nmoll1 during 20 minutes of 12.5 ng per kg IBW (Ideal
Body Weight) per minute adrenaline infusion), a level that
would stimulate lipolysis (Webber et al., 1994).
Catecholamines have long been implicated in appetite
regulation as clinical appetite suppressants in obese
patients (Lean and Finer, 2006) and it is demonstrated that
they exert regulatory effects on the expression of mRNA
leptin and circulating leptin concentrations (Ricci and
Fried, 1999). The current study is the first to investigate the
role of short-term increases in adrenergic activity on the
acute appetite response following exercise in humans. It
was observed that 20 minutes of adrenaline infusion did not
affect acute appetite or serum leptin concentration and
leptin concentrations did not change after 20 minutes of
moderate-intensity exercise. This is in agreement with
others that found decreases in leptin only after prolonged
moderate intensity exercise in trained men (Zaccaria et al.,
2013) and overweight women (Tiryaki-Sonmez et al.,
2013) or a delayed leptin reduction in active individuals
within a 24 hour timeframe post-exercise (King et al.,
2015). Notably, exercise-induced NA increase but not other
biochemical factors (i.e., cortisol or FFA) was suggested to
account for the reduction in post-exercise circulating leptin
(Zaccaria et al., 2013). However, these studies either did
not measure subsequent effects on appetite/satiety feelings
post exercise or found no compensatory appetite response
(King et al., 2015). As the exercise-induced appetite reg-
ulatory response, both hormonal and behavioural, might
diverge in the presence of obesity (Heden et al., 2013),
whether there is an interplay between adrenergic activity,
leptin response and appetite expression after exercise
remains to be clarified utilising different modes of exercise
in individuals with different body weights.
Furthermore, research in physical exercise and appetite
regulation has shown that single bouts of exercise might
suppress the orexigenic ghrelin while simultaneously ele-
vating anorexigenic signals peptide YY (PYY), glucagon-
like peptide-1 (GLP-1), cholecystokinin (CCK) and pan-
creatic polypeptide (PP) (Zouhal et al., 2019). These
observations have been reported mainly in lean, physically
active males whereas evidence in females and particularly
in individuals with obesity is sparse and contradictory. It is
Table 4. Serum leptin, blood glucose, plasma FFA, plasma adrenaline and noradrenaline (NA) concentrations during the EXP-2, n ¼ 9.
p value
Interventions (-60 min) (0 min) (20 min) (80 min) Time Intervention
Intervention
x Time
Serum leptin
(ng.ml1)
Adrenaline
infusion
63.68 + 7.77 63.20 + 8.11 61.98+ 8.58 67.70+ 10.49 p ¼ 0.068 p ¼ 0.688 p ¼ 0.961
Saline
infusion
65.80 + 8.15 65.86 + 8.07 65.31+ 9.18 68.90+ 7.73
Blood glucose
(mmol.l1)
Adrenaline
infusion
4.79 + 0.34 4.59+ 0.09 4.76+ 0.82 4.530+ 0.07 p ¼ 0.136 p ¼ 0.696 p ¼ 0.532
Saline
infusion
5.03 + 0.27 4.72+ 0.06 4.60+ 0.05 4.575+ 0.03
Plasma FFA
(mmol.l1)
Adrenaline
infusion
0.75 + 0.15 0.84+ 0.13 1.09+ 0.17a 0.82+ 0.11 p ¼ 0.010 p ¼ 0.025 p ¼ 0.083
Saline
infusion
0.56 + 0.11 0.57+ 0.13 0.65+ 0.15 0.70+ 0.10
Plasma
adrenaline
(nmol.l1)
Adrenaline
infusion
– 0.17+ 0.26 – –
Saline
infusion
– 0.16+ 0.20 – –
Plasma NA
(nmol.l1)
Adrenaline
infusion
– 1.59+ 0.19 2.32+ 0.19 – p ¼ 0.010 p ¼ 0.063 p ¼ 0.060
Saline
infusion
– 1.49+ 0.26 1.61+ 0.26 –
Values are estimated marginal means+ SEM. Analysis was conducted by ANOVA with repeated measures adjusted for multiple comparisons using
Bonferroni corrections.
aSignificant differences between infusion trials (adrenaline infusion vs saline infusion: at 20 min FFA; p ¼ 0.032) (pairwise comparisons, adjustment for
multiple comparisons: Bonferroni). Post-adrenaline infusion values of circulating adrenaline concentrations were not determined due to unresolved co-
eluting peaks with adrenaline.
ANOVA: analysis of variance; FFA: free fatty acids.
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also suggested that exercise training in women with obesity
might influence the regulation of food intake via improved
leptin sensitivity (Martins et al., 2013). New evidence from
animal studies indicates that leptin might enhance the
effects of gut-satiety hormones, highlighting the impor-
tance of interactions among the feeding-related hormones
that probably lead to an integrated anorectic signal
(Akieda-Asai et al., 2014). Future studies need to measure
leptin in conjunction with the other appetite-regulating
peptides (acylated ghrelin, PYY, GLP-1, CCK and PP) to
enable a better understanding of how exercise-induced
responses to appetite-regulating hormones might differ in
obesity (Dorling et al., 2018).T
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Table 6. Gas exchange, energy expenditure and substrate
oxidation in EXP-1 (at rest and during 20 min of exercise) and in
EXP-2 (at rest and during 20 min of adrenaline/saline infusion.)
Trials Rest
20 min
intervention
VO2 (L.min
1) Exercise plus
placebo
0.3+ 0.04 1.4 + 0.3
Exercise plus
a/b blocker
0.3+ 0.06 1.3 + 0.4
Saline infusion 0.2+ 0.09 0.3 + 0.05
Adrenaline
infusion
0.3+ 0.06 0.3 + 0.05
VCO2 (L.min
1) Exercise plus
placebo
0.2+ 0.06 1.1 + 0.2
Exercise plus
a/b blocker
0.2+ 0.07 1.1 + 0.3
Saline infusion 0.2+ 0.07 0.2 + 0.04
Adrenaline
infusion
0.2+ 0.05 0.2 + 0.03
Energy expenditure
(kcalmin1)
Exercise plus
placebo
1.3+ 0.1 6.8 + 1.5
Exercise plus
a/b blocker
1.3+ 0.3 6.4 + 2.0
Saline infusion 1.1+ 0.4 1.2 + 0.2
Adrenaline
infusion
1.3+ 0.3 1.4 + 0.2
CHO oxidation
(gmin1)
Exercise plus
placebo
0.08+ 0.33 0.58 + 0.45
Exercise plus
a/b blocker
0.10+ 0.15 0.55 + 0.27
Saline infusion 0.06+ 0.15 0.07 + 0.09
Adrenaline
infusion
0.08+ 0.12 0.03 + 0.15
Fat oxidation
(gmin1)
Exercise plus
placebo
0.10+ 0.13 0.48 + 0.21
Exercise plus
a/b blocker
0.09+ 0.04 0.45 + 0.15
Saline infusion 0.10+ 0.06 0.15 + 0.07
Adrenaline
infusion
0.10+ 0.06 0.14 + 0.07
Values are estimated marginal means+ SEM. No significant differences
were found between trials in EXP-1 or EXP-2.
CHO: Carbohydrate; EXP: experiment.
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With regard to the effect of adrenaline infusion on acute
appetite control in obese women, previous studies reported
reduced circulating leptin concentrations after 60 minutes
of adrenaline infusion (0.010 g/kg fat free mass/min),
suggesting that a decrease in obesity-related leptinemia
could stimulate a compensatory appetite response but this
was not assessed (Couillard et al., 2002). The lack of any
significant adrenaline-induced decrease in serum leptin
concentrations in the present study may be due to the
shorter period of adrenaline infusion compared to previous
studies, which found reduced circulating leptin levels after
infusions of 60 to 180 minutes (Couillard et al., 2002).
Secondly, the large variability in leptin response to adre-
naline previously observed in human obesity, namely, low-
and high-leptin responders, could account for the present
unchanged leptin concentrations during adrenaline infusion
and could indicate a potential heterogeneity in leptin sen-
sitivity among obese individuals (Couillard et al., 2002). It
is possible that adrenaline-induced changes in leptin could
induce changes in appetite/satiety sensations and food
intake in the short term, but additional work is necessary to
understand the complexity of this physiological mechan-
ism, the timeframe of its action and whether there are
differences in the regulation of appetite and food intake
between low- and high-leptin responders to adrenaline.
The current study was not able to reproduce the asso-
ciation between leptin and appetite sensations that was
found in our earlier study (Tsofliou et al., 2003). There was
no evidence for a difference in EI 1 hour after the moderate
exercise with placebo (average 813 kcal) compared to a/b-
adrenergic blockade (average kcal 900) (p ¼ 0.2). When
the REI was additionally calculated for the exercise trials,
no difference in REI incurred between exercise with pla-
cebo (677 kcal) and exercise with a/b-adrenergic blockade
(772 kcal). Previous data from walking studies reported no
compensatory response in absolute EI in lean and obese
individuals and no changes in relative EI or a significant
decrease when the median energy deficit of exercise was
around 335 kcal (Schubert et al., 2013). The present find-
ings indicate that a/b-adrenergic blockade was not able to
induce a different appetite response to exercise with pla-
cebo and did not trigger a compensatory response in EI and
appetite sensations after an acute exercise-induced energy
deficit. These findings, however, were derived from a small
sample and require further verification.
In the present study, labetalol 100 mg resulted in a lower
plasma FFA concentration immediately after and 1 hour
after moderate exercise (0.49 nmol.l1, 0.59 nmol.l1
respectively) compared to placebo (0.74 nmol.l1, 0.73
nmol.l1 respectively) possibly by blocking the b-receptor
mediated lipolysis (Ladage et al., 2013). The a/b-adrener-
gic blockade also induced a significant increase in
post-exercise blood glucose concentration (4.9 mmol.l1)
compared to placebo (4.5 mmol.l1). These results are
supported by earlier studies (Hartling et al., 1980). How-
ever, they are disputed by recent reports suggesting that b
blockers differ in terms of their mechanism of action and
their effects on glucose and lipid metabolism with respect
to their molecular pharmacological mechanisms (Ladage
et al., 2013) and particularly, nonvasodilating b blockers
are associated with a worsening of glycaemic and lipidic
control at rest (Fonseca, 2010). With regard to a blockade,
100 mg labetalol did not produce significant differences in
resting and post-exercise HR. This is in line with previous
studies showing that labetalol at doses of 100, 200 and
400 mg did not alter resting HR compared to placebo in
healthy males (Beachen et al., 2002). However, little evi-
dence has indicated a dose-dependent reduction in post-
exercise HR at 1 and 2 hours (Tham et al., 1993).
The present findings suggest that combined a/b-adre-
nergic blockade during moderate-intensity exercise does
not influence appetite/satiety sensations or subsequent food
intake following exercise in obese women. The changes in
blood glucose and plasma FFA suggest 100 mg of a/b-
adrenergic blocker was sufficient to induce b-adrenergic
blockade. Labetalol was chosen as a safe and well under-
stood a/b blocker; however, it has greater affinity for
b- than a-adrenoceptors (MacCarthy and Bloomfield,
1983). For this reason, any conclusions with respect to
a-adrenoceptor blockade should be drawn with caution.
Labetalol decreased circulating FFA and increased glucose
concentrations, which indicate inhibition of catecholamine-
stimulated lipolysis and confirm the primarily b-adreno-
ceptor blockade. There is no simple way to know if a
blockade was adequate. There is evidence that attributes
the anorexigenic effect of catecholamines to a-adreno-
ceptors in the brain (Wellman et al., 1993). It is this
effect that a popular class of anti-obesity drugs exploits
to reduce eating behaviour (e.g., sibutramine) by blocking
NA reuptake through activation of brain a1-adrenoceptor
receptors (Lean, 2001).
Study limitations
The monitoring period of appetite response was relatively
brief in our study. According to recent findings, changes
in appetite hormones could emerge over the following
24 hours (King et al., 2015). Determining the EI response
might also require multiple ad libitum meals, rather than
single feeding episodes (Deighton and Stensel, 2014). In
our study, all women were premenopausal but menstrual
cycle was not controlled for in the study design to account
for the perceived confounding effect of the menstrual cycle
on appetite sensations, appetite-regulating hormones and
EI (Brennan et al., 2009). However, we did not find any
differences in appetite responses and EI between the
interventions, which could have been confounded by
cyclical changes in sex hormones in our women.
Conclusions
In conclusion, inhibition of exercise-induced adrenergic
activity by combined a/b-adrenergic blockade and moder-
ate increases in adrenergic activity induced by intravenous
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adrenaline infusion did not significantly affect acute appetite
ratings or ad libitum intake in obese premenopausal women.
Testing with a more potent a blockade may be necessary to
trigger a detectable effect and elucidate the role of adre-
nergic activity in exercise-induced anorexia. In this way we
could conclude with complete confidence that the observed
anorexic effect of exercise on appetite in obese women is not
mediated by increased adrenergic activity. Finally, to defi-
nitively exclude sympathetic system involvement in exercise-
related appetite regulation, the effects of more selective
a-adrenergic stimulation on leptin-mediated appetite sensi-
tivity after exercise should be investigated.
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